近日,Revolution Medicines, Inc. 药物化学总监 Yang Liu 博士、高级科学家 Kristof Pota 博士一行到访美迪西南汇研发中心。美迪西药物发现与药学研究事业部总裁段茂圣博士、化学副总裁王健博士等热情接待。双方围绕项目进展、数据流转与合作方向等议题深入沟通,并就后续项目的高效推进凝聚共识。访问期间,美迪西向 Revolution Medicines 颁发"卓越客户奖",致敬双方多年来在药物发现领域携手攻坚、互信共赢的跨国研发伙伴关系。
近百人团队三年深耕,筑牢互信研发范式
依托药物发现 FTE 团队,美迪西与 Revolution Medicines 深度协同,共同应对药物发现阶段的技术挑战。三年来,近百名美迪西化学研发人员持续投入这一跨国协作,以稳定交付与严格质控,筑牢双方互信的研发合作范式。
颁奖与致意
颁奖现场,美迪西向 Revolution Medicines 颁发"卓越客户奖"。段茂圣博士高度评价 Revolution Medicines 多年来深耕 RAS——这一曾被视为"不可成药"的靶点——所展现的长期主义坚守,并祝贺由 Revolution Medicines 研发的 Rasonque(daraxonrasib)于 2026 年 8 月获得美国 FDA 批准,用于治疗转移性胰腺癌,这一里程碑正是其科学远见与执行力的印证。同时,"卓越客户奖"致敬的并非某一个项目,而是双方三年多来在药物发现领域建立的相互成就与双向互信:同频的科学理念、严苛的研发标准与持久的信任,是这份荣誉真正的基石。Revolution Medicines 对科学的执着追求,也持续激励美迪西突破技术边界。
深度技术对话,共探创新合作机遇
座谈会上,王健博士介绍了美迪西的发展概况与从靶点发现到 IND 申报的一体化研发平台能力。美迪西建立了符合国际规范的质量体系,拥有 NMPA、OECD GLP 资质,符合 FDA GLP 标准,并通过 AAALAC 国际认证;同时搭建了 ADC/AOC、PROTAC、CGT、核酸、多肽、抗体等前沿技术服务平台。双方围绕跨地域数据流转、技术对接、项目管理及未来合作方向进行了深入探讨,就持续提升跨国联合研发效率充分交换意见。
实验室参观
随后,Revolution Medicines 一行参观了美迪西研发实验室,实地考察了化学、原料药及寡核苷酸等药学研究实验室和临床前研究设施,对美迪西的研发硬件实力与质量管控体系有了直观了解。
创新药研发是一场漫长远征,需要合作双方坚守共识与长期主义。美迪西由衷感谢 Revolution Medicines 多年来的信任与托付。未来,美迪西将持续输出高质量、高效率的新药研发服务,携手 Revolution Medicines 及全球创新药企,立足临床未竟需求,不断把药物研发领域的"不可能"变为"可能"。
关于Revolution Medicines
Revolution Medicines, Inc.(纳斯达克代码:RVMD)是一家全球性、商业化阶段的肿瘤公司,致力于发现、开发并交付面向 RAS 成瘾性癌症患者的创新药物。公司依托差异化的 RAS(ON) 三复合抑制剂平台,正在推进一个广泛、一体化的口服 RAS(ON) 抑制剂组合,旨在直接靶向 RAS 的活性致癌状态。更多信息请访问 www.revmed.com。
关于美迪西
美迪西(股票代码:688202.SH)成立于 2004 年,专注于为全球制药企业、研究机构及科研工作者提供全方位的临床前新药研发服务。公司构建了覆盖药物发现、药学研究至临床前研究的一站式综合研发平台,并在 ADC/AOC、小核酸、多 (环)肽、TPD, RIPTAC等前沿领域搭建了服务平台。公司建立了符合国际规范的质量体系,已获得中国 NMPA、美国 FDA、欧盟 OECD 等 GLP 认证以及 AAALAC 国际认证。目前,公司在上海和Boston拥有约 9.2 万平方米研发实验室。至 2026 年 6 月末,公司已为全球超 2000 家客户提供药物研发服务,参与研发完成的新药项目已有 691 件 IND临床批件。美迪西将继续携手国内外合作伙伴共同推动药物创新,为人类健康贡献力量。欢迎访问公司官网 www.medicilon.com.cn 了解更多详情。
A Three-Year Cross-Border Partnership Backed by Nearly 100 Medicilon Scientists — Medicilon Presents the "Outstanding Client Award" to Revolution Medicines
Recently,Dr. Yang Liu, Director of Medicinal Chemistry, and Dr. Kristof Pota, Senior Scientist of Revolution Medicines, Inc., visited Medicilon's Nanhui R&D Center. Dr. Maosheng Duan, President of the Drug Discovery and CMC Divisions, and Dr. Jian Wang, Vice President of Chemistry, extended a warm welcome to the delegation. The two parties held in-depth discussions on project progress, data transfer and future collaboration, and reached consensus on the efficient execution of ongoing programs. During the visit, Medicilon presented Revolution Medicines with the "Outstanding Client Award" in honor of the multi-year, trust-based R&D partnership the two companies have built in drug discovery.
A Three-Year Commitment from Nearly 100 Scientists, Forging a Trusted R&D Model
Leveraging its dedicated drug discovery FTE team, Medicilon has worked in close collaboration with Revolution Medicines to meet demanding drug discovery challenges. Over the past three years, nearly 100 Medicilon chemistry researchers have supported this cross-border partnership, building a trusted R&D model through consistent delivery and rigorous quality control.
The Award Ceremony
At the award ceremony, Medicilon presented Revolution Medicines with the "Outstanding Client Award." Dr. Duan spoke highly of Revolution Medicines' long-standing commitment to RAS — a target once regarded as "undruggable" — and congratulated the company on the U.S. FDA approval in August 2026 of Rasonque (daraxonrasib), its therapy for metastatic pancreatic cancer: a milestone that reflects the team's scientific vision and execution. The award recognizes not a single program, but the mutual trust and shared achievement the two companies have built over more than three years in drug discovery — aligned scientific standards, rigorous quality and enduring trust form its true foundation. Revolution Medicines' dedication to science continues to inspire Medicilon to push its own technical boundaries.
In-Depth Technical Dialogue to Explore New Avenues of Collaboration
At the symposium, Dr. Jian Wang presented Medicilon's corporate profile and its integrated R&D platform spanning from target identification to IND-enabling studies. Medicilon maintains an internationally compliant quality system, holding NMPA and OECD GLP accreditations, meeting FDA GLP requirements and AAALAC international certification. The company has also established technology service platforms in cutting-edge modalities, including ADC/AOC, PROTAC, CGT, oligonucleotides, peptides and antibodies. The two parties held in-depth discussions on cross-region data workflows, technical coordination, project management and future collaboration, and exchanged views on how to further improve the efficiency of joint cross-border R&D.
Laboratory Tour
The Revolution Medicines delegation also toured Medicilon's R&D laboratories, inspecting the chemistry, API and oligonucleotide pharmaceutical research laboratories as well as the preclinical research facilities, and gaining first-hand insight into Medicilon's R&D infrastructure and quality management system.
Innovative drug discovery is a long expedition that calls for shared commitment and long-term thinking from both partners. Medicilon sincerely appreciates the trust Revolution Medicines has placed in us over the years. Moving forward, Medicilon will continue to deliver high-quality, efficient new drug R&D services. Together with Revolution Medicines and biopharmaceutical innovators worldwide, we will stay focused on unmet clinical needs and keep turning the "impossible" in drug discovery into reality.
About Revolution Medicines, Inc.
Revolution Medicines, Inc. (Nasdaq: RVMD) is a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS. For more information, visit www.revmed.com.
About Medicilon
Founded in 2004, Medicilon (Stock Code: 688202.SH) is dedicated to delivering comprehensive preclinical drug R&D services to pharmaceutical enterprises, research institutions, and scientific investigators worldwide. The company has established a one-stop integrated R&D platform encompassing drug discovery, pharmaceutical research, and preclinical research, and has developed service platforms in cutting-edge fields including ADC/AOC, RNAi, peptides (including macrocyclic peptides), TPD, and RIPTAC. The company has instituted a quality system compliant with international standards and has secured GLP certifications from China's NMPA, the U.S. FDA, and the EU's OECD, along with AAALAC International accreditation. At present, the company operates approximately 92,000 square meters of R&D laboratory space across Shanghai and Boston. As of the end of June 2026, the company has provided drug R&D services to over 2,000 clients globally and has supported 691 IND approvals. For more information, visit www.medicilon.com.
股票
板块
用户
资讯
评论 (0)